Sue MacLemanSue has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive with senior roles in corporate, medical, commercial and business development. Sue has served as CEO and Board member of several ASX and NASDAQ listed companies in the sector and is currently Chair - Anatara Lifesciences (ASX:ANR), Chair - MTPConnect (Medical Technology and Pharmaceuticals Industry Innovation Growth Centre), Non-Executive Director - Oventus Medical Ltd (ASX: OVN), Novita Healthcare Ltd and veski.
Sue is also appointed to a number of academic and government advisory committees. Her broad commercial experience is underpinned by graduate qualifications in pharmacy and post graduate qualifications in corporate governance, commercial law, business administration and marketing.
Interim CEO and Director
Dr Tracie RamsdaleTracie holds a PhD in Biochemistry from the University of Queensland, a Master of Pharmacy from the Victorian College of Pharmacy and a Bachelor of Applied Science (Chemistry) from the Royal Melbourne Institute of Technology.Following a successful career as a Principal Investigator and Commercial Manager of the Centre for Drug Design and Development at the University of Queensland, Tracie co-founded Alchemia Limited, a drug discovery and development company and served as the company’s CEO for almost 10 years. During this time, she was responsible for multiple financing transactions and licensing the company’s technology to major international pharmaceutical and manufacturing partners.
Dr Ramsdale has served on a number of industry and government advisory groups and provided independent consulting advice to the biotechnology industry, academia and government.
Tracie is a Fellow of the Australian Academy of Technological Sciences and Engineering, and a member of the Australian Institute of Company Directors.
Dr Jane RyanJane has over 30 years of international experience in the pharmaceutical and biotechnology industries where she has held executive roles in management of research and development programs as well as business development and alliance management. Jane has worked both in Australia, the US and UK with companies including Peptech, Roche, Cambridge Antibody Technology and Biota Holdings. Throughout her career, she has led many successful fundraising campaigns and licensing initiatives including the awarding of a $230m US Government contract.
Jane currently chairs the Advisory Board at the ithree Institute at the University of Technology Sydney (UTS) which studies how microbes grow, live, adapt and survive. She is also currently a Board Member of Victorian endowment for Science Knowledge and Innovation (veski), Part time Vice President Research and Development at Reef Pharmaceuticals and advisor to Opal Pharmaceuticals. Jane was previously a Board Member of Diabetes Victoria, TechInSA, and the Diabetes Vaccine Development Centre. Jane is assisting CSIRO with its GMP protein manufacture initiative.
Stephen DenaroStephen has extensive experience in mergers and acquisitions, business valuations, accountancy services, and income tax compliance gained from positions as Company Secretary and Chief Financial Officer of various public companies and with major chartered accountancy firms in Australia and the United Kingdom. He provides company secretarial services for a number of start-up technology and ASX listed and unlisted public companies.
Stephen has a Bachelor of Business in Accountancy, Graduate Diploma in Applied Corporate Governance and is a member of the Institute of Chartered Accountants in Australia and the Australian Institute of Company Directors.